Other OTC - Delayed Quote USD

Astellas Pharma Inc. (ALPMY)

9.55 +0.01 (+0.10%)
At close: April 26 at 3:59 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ALPMY

Recent News: ALPMY

View More
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting

Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
PR Newswire 4 days ago
Pharmas form joint venture to jumpstart Japanese drug research

Pharmas form joint venture to jumpstart Japanese drug research
BioPharma Dive 6 days ago
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs

Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
PR Newswire 6 days ago
U.S. Stocks Erase Early Gains

U.S. Stocks Erase Early Gains
The Wall Street Journal 12 days ago
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
PR Newswire 30 days ago
Astellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

Astellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
PR Newswire last month
Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer

Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
PR Newswire last month
Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting

Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting
PR Newswire last month

Q4 2023 Taysha Gene Therapies Inc Earnings Call
Thomson Reuters StreetEvents last month
With new data, Bayer readies rival to Astellas menopause drug

With new data, Bayer readies rival to Astellas menopause drug
BioPharma Dive last month
FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA® (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children

FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA® (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children
PR Newswire last month
Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan

Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan
PR Newswire last month
View More

Related Tickers

DSNKY Daiichi Sankyo Company, Limited
32.20
+4.34%
 
OPHLY Ono Pharmaceutical Co., Ltd.
4.8600
+1.46%
 
GLAXF GSK plc
19.85
0.00%
 
DSKYF Daiichi Sankyo Company, Limited
31.85
+5.12%
 
SNPHF Santen Pharmaceutical Co., Ltd.
9.26
0.00%
 
JNJ.MU Johnson & Johnson
137.28
+0.45%
 
SNPHY Santen Pharmaceutical Co., Ltd.
9.39
-1.78%
 
OTSKY Otsuka Holdings Co., Ltd.
20.47
+2.20%
 
CHGCY Chugai Pharmaceutical Co., Ltd.
15.38
-1.35%
 
BAYRY Bayer Aktiengesellschaft
7.39
+1.65%